Cube Labs: Transforming Scientific Discovery into Scalable Healthcare Innovation

Italy-based Cube Labs is redefining healthcare venture building by bridging the gap between academic research and global markets—delivering measurable social impact through an integrated, repeatable innovation model.

Cube Labs S.p.A. is not just another player in the healthcare innovation space—it is Italy’s first dedicated venture builder for life sciences, with a bold mission to transform high-potential academic research into globally scalable health solutions. Co-founded by Filippo Surace, Renato Del Grosso, and Massimo Fiocchi, Cube Labs operates at the intersection of scientific discovery, entrepreneurial execution, and social impact.

Rather than functioning as a traditional incubator or venture capital fund, Cube Labs pioneered a purpose-built venture builder platform. This unique model consolidates all the critical phases of biomedical innovation—technology scouting, IP strategy, regulatory planning, clinical development, and market access—into a streamlined, end-to-end structure. The goal is clear: ensure promising research doesn’t stagnate in laboratories but reaches patients and populations worldwide.

Cube Labs’ institutional partnership with INBB (Istituto Nazionale Biostrutture e Biosistemi), a research consortium under Italy’s Ministry of University and Research, gives it access to over 24 universities and scientific centres across Italy. This privileged pipeline of translational research has enabled Cube Labs to identify breakthrough technologies in biotech, medtech, diagnostics, and nutraceuticals, which are then co-developed into ventures with long-term commercial viability.

In just four years, Cube Labs has launched 17 healthcare startups, secured over 60 patents, and brought two products to market. In March 2023, it successfully listed on the Milan Stock Exchange (Euro Growth Milan – Professional Segment)—a milestone not only for the company but also for Italy’s broader life sciences ecosystem.

Cube Labs’ international ambitions are also well underway. A strategic partnership with Modi Global Enterprises in India is helping export its venture-building model to one of the world’s fastest-growing healthcare markets. The aim: to replicate Cube Labs’ success in delivering ethical, scalable innovation to populations in greatest need.

What sets Cube Labs apart is its unwavering commitment to accessibility and equity. It aligns its operations with ESG principles and the UN Sustainable Development Goals, pursuing inclusive, high-impact technologies while embedding sustainability into each venture. Its modular model offers researchers a scientific infrastructure, business support, and patient capital—freeing them to focus on R&D while Cube Labs steers the commercial trajectory.

Cube Labs is not simply building companies—it is building capacity across systems. It measures success by more than financial metrics, prioritising improvements in patient outcomes, health access, and systemic innovation. Recent accolades, including the “Champion of Scalable Market-Ready Healthcare Ventures – Italy 2025” award from CFI.co and the Motore Italia 2025 “Innovation” Award from Milano Finanza, affirm its leadership status in European venture building.

As private markets grow more impact-driven, Cube Labs offers a blueprint for integrating scientific excellence with scalable infrastructure and long-term value creation. In its venture builder model, the lab truly meets the market—and the result is healthier lives, stronger ecosystems, and innovation that serves the world.